The treatment landscape for multiple myeloma is changing rapidly, with antibody-drug conjugates (ADCs), bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy emerging beyond the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results